Vysis launches fluorescence in situ hybridisation (FISH) equipment:
This article was originally published in Clinica
Executive Summary
Vysis has launched its HYBrite automated system for denaturation and hybridisation of in situ DNA probe procedures. The system reduces the time for fluorescence in situ hybridisation (FISH) procedures. The company has also launched its Quips genetic imaging software and Quips XL and LS genetic workstations for FISH procedures, comparative genomic hybridisation and karyotyping analyses. Quips software allows capture, enhancement, analysis and printing of high-quality images that identify genetic aberrations associated with pre- and postnatal diseases and cancer. The workstations use a fluorescence microscope to visualise and enhance fluorescent signals.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.